As of today (2022-05-26), Guardant Health's share price is $36.49. Guardant Health's Tangible Book per Share of Mar. 2022 for the quarter that ended in Mar. 2022 was $5.06. Hence, Guardant Health's Price to Tangible Book Ratio of today is 7.21.
The historical rank and industry rank for Guardant Health's Price-to-Tangible-Book or its related term are showing as below:
GH'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.79 Med: 10.26 Max: 18.63
Current: 7.21
During the past 6 years, Guardant Health's highest Price to Tangible Book Ratio was 18.63. The lowest was 6.79. And the median was 10.26.
GH's Price-to-Tangible-Book is ranked worse than 79.17% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.33
vs GH: 7.21
A closely related ratio is called PB Ratio. As of today, Guardant Health's share price is $36.49. Guardant Health's Book Value per Sharefor the quarter that ended in Mar. 2022 was $5.23. Hence, Guardant Health's P/B Ratio of today is 6.98.
Guardant Health Price-to-Tangible-Book Historical Data
The historical data trend for Guardant Health's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Guardant Health Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Price-to-Tangible-Book
-
6.79
9.45
10.10
16.22
Guardant Health Quarterly Data
Dec16
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Price-to-Tangible-Book
18.63
16.34
18.37
16.22
13.08
Competitive Comparison
For the Diagnostics & Research subindustry, Guardant Health's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health Price-to-Tangible-Book Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Guardant Health's Price-to-Tangible-Book falls into.
Guardant Health Price-to-Tangible-Book Calculation
Guardant Health's price-to-tangible-book ratio for today is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Guardant Health Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Guardant Health's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.78(2.09%) Volume: 1,376,126 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:GH has been successfully added to your 
